A science-led global healthcare
company with a special purpose:
to help people do more, feel
better, live longer.
We have 3 global businesses that discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.
Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.
Our Pharmaceuticals business has a broad portfolio of innovative and established medicines with leadership positions in respiratory and HIV. We are strengthening our pipeline through a focus on science related to the immune system, human genetics and advanced technologies.
We are the leading vaccines company in the world, delivering over 2 million vaccine doses every day to people living in over 150 countries. Our portfolio helps protect people throughout their lives. We have recently introduced breakthrough vaccines for shingles and meningitis B.
We are the world’s largest Consumer Healthcare company following our new joint venture with Pfizer. We develop and market a portfolio of consumer preferred and expert-recommended brands including Sensodyne, Parodontax, Poligrip, Advil, Voltaren, Panadol, Centrum, Otrivin and Theraflu.
Everyone at GSK is focused on our 3 long-term priorities – Innovation, Performance, Trust, all powered by our performance-focused culture.
We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.
34
new medicines in development targeting the patient’s immune system to treat disease (as of May 2019)
We drive growth and profitability by disciplined investment in our strategic priorities, attracting and developing great people and high quality execution.
No.1
dolutegravir in the most prescribed core agent for HIV treatments worldwide
We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer.
1st
single dose medicine approved in 60 years for treating relapsing malaria
To help people do more, feel
better, live longer.
2 locations in Poland – Poznań and Warsaw.
Over 2,300 people hired directly by GSK.
300 different, high-quality pharmaceutical medicines and healthcare products delivered to Polish patients and consumers.
Over 2,400 vendors and business partners we cooperate with:
- 12M PLN invested in clinical trails in Poland
- 2B PLN invested in the healthcare industry in Poland for 20 years
Thanks to the purchase of the factory in Poznań in 1998 and investments made in recent years, we have become one of the largest foreign investors in the Polish pharmaceutical industry. We work with the local healthcare industry to support progress in medicine and improve the quality of healthcare.
We carry out social and preventative actions that increase health awaraness among Poles (e.g., Żółty Tydzień, Powstrzymaj Rotawriusy, support for Inform’s campaign “Zaszczep się wiedzą”). We are a leading employer and a responsible business partner for nearly 2,400 entities in Poland.
White List of CSR Polityka in the VIII list of socially responsible companies for 2018.
Seventh place in the general classification of the Ranking of Responsible Companies and second place in the category of companies operating in healthcare
GSK is the Laureate of the Golden Super Business Laurel 2019 in the Medicine and Business category
GSK is the laureate of Wprost Innovators in the category Science for mepolizumab (Nucala)
First place in the Most Desirable Employers ranking in the opinion of specialists and managers in the Pharmaceutical Companies category
First place in the Ranking of Responsible Companies